KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Depreciation & Amortization (CF): 2017-2025

Historic Depreciation & Amortization (CF) for Aquestive Therapeutics (AQST) over the last 9 years, with Sep 2025 value amounting to $139,000.

  • Aquestive Therapeutics' Depreciation & Amortization (CF) fell 12.58% to $139,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $565,000, marking a year-over-year decrease of 45.57%. This contributed to the annual value of $718,000 for FY2024, which is 46.62% down from last year.
  • As of Q3 2025, Aquestive Therapeutics' Depreciation & Amortization (CF) stood at $139,000, which was down 0.71% from $140,000 recorded in Q2 2025.
  • Aquestive Therapeutics' Depreciation & Amortization (CF)'s 5-year high stood at $755,000 during Q1 2021, with a 5-year trough of $139,000 in Q1 2025.
  • In the last 3 years, Aquestive Therapeutics' Depreciation & Amortization (CF) had a median value of $205,000 in 2024 and averaged $225,545.
  • As far as peak fluctuations go, Aquestive Therapeutics' Depreciation & Amortization (CF) rose by 17.63% in 2023, and later tumbled by 68.52% in 2024.
  • Aquestive Therapeutics' Depreciation & Amortization (CF) (Quarterly) stood at $731,000 in 2021, then slumped by 45.69% to $397,000 in 2022, then rose by 17.63% to $467,000 in 2023, then tumbled by 68.52% to $147,000 in 2024, then fell by 12.58% to $139,000 in 2025.
  • Its Depreciation & Amortization (CF) stands at $139,000 for Q3 2025, versus $140,000 for Q2 2025 and $139,000 for Q1 2025.